(Q37780003)

23 August 2017

1 reference

title

Cerebrospinal fluid concentrations of antituberculosis agents in adults and children (English)

1 reference

23 August 2017

0 references

P R Donald

1

1 reference

23 August 2017

publication date

14 August 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

90

1 reference

23 August 2017

issue

5

1 reference

23 August 2017

page(s)

279-292

1 reference

Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Pharmacokinetic aspects of the treatment of infections in the central nervous system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Pharmacokinetic optimisation of the treatment of bacterial central nervous system infections.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

The early bactericidal activity of anti-tuberculosis drugs: a literature review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Clinical implications of isoniazid blood levels in pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

The influence of human N-acetyltransferase genotype on the early bactericidal activity of isoniazid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

C.S.F.--isoniazid levels in tuberculous meningitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

The treatment of tuberculous meningitis in infants with streptomycin and isonicotinic acid hydrazide (isoniazid); a preliminary report of six patients under the age of two years treated without intrathecal medication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Kinetics of isoniazid transfer into cerebrospinal fluid in patients with tuberculous meningitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Effect of steroids on cerebrospinal fluid penetration of antituberculous drugs in tuberculous meningitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Cerebrospinal fluid drug concentrations and the treatment of tuberculous meningitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 month

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Kinetic studies on rifampicin. I. Serum concentration analysis in subjects treated with different oral doses over a period of two weeks

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Binding of rifampicin by human plasma proteins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Serum Rifampicin Levels in Patients with Tuberculosis : Effect of P-Glycoprotein and CYP3A4 Blockers on its Absorption

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Cerebrospinal Fluid Concentrations of Rifampin in Meningeal Tuberculosis1,2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Pharmacokinetics, cerebrospinal fluid concentration, and safety of intravenous rifampin in pediatric patients undergoing shunt placements

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Penetration of fusidic acid and rifampicin into cerebrospinal fluid in low-grade inflammatory meningitis caused by Staphylococcus epidermidis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Effect of antituberculosis drug resistance on response to treatment and outcome in adults with tuberculous meningitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

The clinical pharmacokinetics of pyrazinamide in HIV-infected persons with tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Cerebrospinal fluid pyrazinamide concentrations in children with tuberculous meningitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

The blood/cerebrospinal fluid partitioning of pyrazinamide: a study during the course of treatment of tuberculous meningitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Novel treatment of meningitis caused by multidrug-resistant Mycobacterium tuberculosis with intrathecal levofloxacin and amikacin: case report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Multidrug-resistant tuberculosis meningitis: clinical problems and concentrations of second-line antituberculous medications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Some observations on dosage and toxicity of kanamycin in premature and full-term infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Intraventricular cerebrospinal fluid antibiotic concentrations in patients with intraventricular infections.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Amikacin Concentration in the Cerebrospinal Fluid of Children with Acute Bacterial Meningitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Cerebrospinal fluid penetration of amikacin in children with community-acquired bacterial meningitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Evolution of central nervous system multidrug-resistant Mycobacterium tuberculosis and late relapse of cryptic prosthetic hip joint tuberculosis: complications during treatment of disseminated isoniazid-resistant tuberculosis in an immunocompromised

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

ANTITUBERCULOUS AGENTS. II. N,N'-DIISOPROPYLETHYLENEDIAMINE AND ANALOGS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Ocular manifestations of ethambutol, Toxic amblyopia after administration of an experimental antituberculous drug

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Concentrations of ethambutol in the cerebrospinal fluid after oral administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Ethambutol in Tuberculous Meningitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Concentration of ethambutol in cerebrospinal fluid in man as a function of the non-protein-bound drug fraction in serum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Penetration of ciprofloxacin into cerebrospinal fluid of patients with bacterial meningitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Penetration of ciprofloxacin into the cerebrospinal fluid of patients with uninflamed meninges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Diffusion of ofloxacin into the cerebrospinal fluid in patients with bacterial meningitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Study of the cerebrospinal fluid penetrability of ofloxacin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Concentrations of ofloxacin in serum and cerebrospinal fluid of patients without meningitis receiving the drug intravenously and orally

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Diffusion of ofloxacin into cerebrospinal fluid of patients with purulent meningitis or ventriculitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Kinetics of ofloxacin and its metabolites in cerebrospinal fluid after a single intravenous infusion of 400 milligrams of ofloxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Levofloxacin disposition in cerebrospinal fluid in patients with external ventriculostomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Multidrug-resistant tuberculous meningitis in children in Durban, South Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Ethionamide: its passage into the cerebrospinal fluid in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Cerebrospinal fluid concentrations of ethionamide in children with tuberculous meningitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

Letter: Treatment of tuberculous meningitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.07.002

10.1016/J.TUBE.2010.07.002

7 January 2021

Identifiers

DOI

1 reference

23 August 2017

1 reference